Episode Details

IRIDEX Corporations fiscal 2025 results showcased robust growth, with full-year revenue reaching $52.7 million, an 8% increase from the previous year. The companys major products, such as Cyclo G6 for glaucoma and retina systems, drove this growth. The fourth quarter was particularly strong, with a 16% jump in revenue to $14.7 million, marking their best quarterly performance. IRIDEX also achieved positive adjusted EBITDA for the first time and generated positive cash flow from operations in the fourth quarter.

Operating expenses were reduced by 22% through streamlining efforts, and sales grew in both U.S. and international markets. Glaucoma probes saw an increase, with retina products, particularly PASCAL systems, leading the way with 22% quarterly growth. Despite challenges in regions like the Middle East and Asia, core demand remained solid.

The company is making strategic moves to improve profitability, including relocating administrative functions out of California for $165,000 in quarterly savings and plans to move headquarters later in 2026 to cut fixed costs by $600,000 annually. They are also shifting manufacturing to lower-cost third parties, expecting gross margin improvements through 2027.

Looking ahead, IRIDEX guides for 2026 revenue between $51 million and $53 million, excluding Middle East sales, translating to 1-5% growth on a pro forma basis compared to last year. Priorities include boosting Cyclo G6 utilization with sales tools like MedScout and expanding PASCAL globally as approvals come in. These steps position IRIDEX for sustainable profitability and cash generation moving forward.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/091a3229d01c8422